Fred Aswad

879 total citations
17 papers, 540 citations indexed

About

Fred Aswad is a scholar working on Immunology, Physiology and Molecular Biology. According to data from OpenAlex, Fred Aswad has authored 17 papers receiving a total of 540 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Immunology, 4 papers in Physiology and 3 papers in Molecular Biology. Recurrent topics in Fred Aswad's work include Immune Cell Function and Interaction (4 papers), Adenosine and Purinergic Signaling (4 papers) and Hemophilia Treatment and Research (3 papers). Fred Aswad is often cited by papers focused on Immune Cell Function and Interaction (4 papers), Adenosine and Purinergic Signaling (4 papers) and Hemophilia Treatment and Research (3 papers). Fred Aswad collaborates with scholars based in United States, Germany and France. Fred Aswad's co-authors include Gunther Dennert, Hiroki Kawamura, Masahiro Minagawa, Sugantha Govindarajan, Pedro Paz, Friedrich Koch‐Nolte, William Schott, Edward H. Leiter, Harvey R. Kaslow and Karen E. Malone and has published in prestigious journals such as Blood, The Journal of Immunology and PLoS ONE.

In The Last Decade

Fred Aswad

17 papers receiving 533 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fred Aswad United States	10	265	243	113	79	71	17	540
Nathalie Jänner Germany	5	56 0.2×	201 0.8×	79 0.7×	142 1.8×	40 0.6×	6	376
Karel P. Alcedo United States	10	96 0.4×	78 0.3×	185 1.6×	48 0.6×	54 0.8×	10	367
Annalisa Moregola Italy	11	40 0.2×	183 0.8×	142 1.3×	37 0.5×	80 1.1×	20	410
James T. Downs United States	7	64 0.2×	83 0.3×	75 0.7×	35 0.4×	58 0.8×	10	379
Heinz‐Günter Thiele Germany	13	327 1.2×	431 1.8×	150 1.3×	341 4.3×	33 0.5×	29	731
A Astaldi Netherlands	16	33 0.1×	305 1.3×	179 1.6×	43 0.5×	82 1.2×	53	693
A. Shamseddine United States	14	23 0.1×	76 0.3×	365 3.2×	110 1.4×	118 1.7×	39	686
Zayda L. Piedra-Quintero Mexico	8	54 0.2×	134 0.6×	151 1.3×	54 0.7×	35 0.5×	9	377
Harutake Sakura Japan	11	87 0.3×	60 0.2×	123 1.1×	147 1.9×	28 0.4×	22	336
Joseph A. Zundell United States	6	56 0.2×	333 1.4×	378 3.3×	147 1.9×	109 1.5×	6	743

Countries citing papers authored by Fred Aswad

Since Specialization

Citations

This map shows the geographic impact of Fred Aswad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fred Aswad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fred Aswad more than expected).

Fields of papers citing papers by Fred Aswad

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fred Aswad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fred Aswad. The network helps show where Fred Aswad may publish in the future.

Co-authorship network of co-authors of Fred Aswad

This figure shows the co-authorship network connecting the top 25 collaborators of Fred Aswad. A scholar is included among the top collaborators of Fred Aswad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fred Aswad. Fred Aswad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Mao, Weifeng, Bing Yao, Yanfeng Zhou, et al.. (2025). Abstract 4229: GTA182: A potentially best-in-class, MTA-cooperative PRMT5 inhibitor for MTAP-deleted advanced solid tumors. Cancer Research. 85(8_Supplement_1). 4229–4229. 1 indexed citations

Bhalla, Manmeet, Joshua Wheeler, Fred Aswad, et al.. (2024). The prostaglandin D2 antagonist asapiprant ameliorates clinical severity in young hosts infected with invasive Streptococcus pneumoniae. Infection and Immunity. 92(5). e0052223–e0052223. 1 indexed citations

Mao, Weifeng, Wei Liu, Yisong Xiao, et al.. (2024). Identification of the KIF18A alpha-4 helix as a therapeutic target for chromosomally unstable tumor cells. Frontiers in Molecular Biosciences. 11. 1328077–1328077. 4 indexed citations

Besnard, Jérémy, James A. Joseph, Ross A. Paveley, et al.. (2022). Abstract 3930: AI-driven discovery and profiling of GTAEXS-617, a selective and highly potent inhibitor of CDK7. Cancer Research. 82(12_Supplement). 3930–3930. 4 indexed citations

Morgan, Hannah L., Su-Yi Tseng, Natacha Szely, et al.. (2019). Evaluation of in vitro Assays to Assess the Modulation of Dendritic Cells Functions by Therapeutic Antibodies and Aggregates. Frontiers in Immunology. 10. 601–601. 39 indexed citations

Garcia, Candy, Hadia Lemar, Christina K. Galang, et al.. (2019). Abstract 3255: A novel small molecule inhibitor of AhR suppresses the polarization and activity of M2 macrophages. Cancer Research. 79(13_Supplement). 3255–3255. 3 indexed citations

Schneidman‐Duhovny, Dina, Natalia Khuri, Guang Qiang Dong, et al.. (2018). Predicting CD4 T-cell epitopes based on antigen cleavage, MHCII presentation, and TCR recognition. PLoS ONE. 13(11). e0206654–e0206654. 24 indexed citations

Joseph, James D., Marcos González‐López, Christina K. Galang, et al.. (2018). Abstract 4719: Small-molecule antagonists of the Aryl Hydrocarbon Receptor (AhR) promote activation of human PBMCs in vitro and demonstrate significant impact on tumor growth and immune modulation in vivo. Cancer Research. 78(13_Supplement). 4719–4719. 9 indexed citations

Mahlangu, Johnny, et al.. (2016). TRUST trial: BAY 86‐6150 use in haemophilia with inhibitors and assessment for immunogenicity. Haemophilia. 22(6). 873–879. 21 indexed citations

10.

Ettinger, Ruth A., Pedro Paz, Eddie A. James, et al.. (2016). T cells from hemophilia A subjects recognize the same HLA-restricted FVIII epitope with a narrow TCR repertoire. Blood. 128(16). 2043–2054. 20 indexed citations

11.

Paz, Pedro, et al.. (2015). Antibody Engineering of Anti-TFPI Bypass Therapeutic BAY 1093884: Isotype Selection and Sequence Optimization. Blood. 126(23). 3496–3496. 6 indexed citations

12.

Kawamura, Hiroki, Fred Aswad, Masahiro Minagawa, Sugantha Govindarajan, & Gunther Dennert. (2006). P2X7 Receptors Regulate NKT Cells in Autoimmune Hepatitis. The Journal of Immunology. 176(4). 2152–2160. 88 indexed citations

13.

Aswad, Fred & Gunther Dennert. (2006). P2X7 receptor expression levels determine lethal effects of a purine based danger signal in T lymphocytes. Cellular Immunology. 243(1). 58–65. 48 indexed citations

14.

Kawamura, Hiroki, Sugantha Govindarajan, Fred Aswad, et al.. (2006). HCV core expression in hepatocytes protects against autoimmune liver injury and promotes liver regeneration in mice†. Hepatology. 44(4). 936–944. 28 indexed citations

15.

Dennert, Gunther & Fred Aswad. (2006). The Role of NKT Cells in Animal Models of Autoimmune Hepatitis. Critical Reviews in Immunology. 26(5). 453–474. 29 indexed citations

16.

Aswad, Fred, Hiroki Kawamura, & Gunther Dennert. (2005). High Sensitivity of CD4+CD25+ Regulatory T Cells to Extracellular Metabolites Nicotinamide Adenine Dinucleotide and ATP: A Role for P2X7 Receptors. The Journal of Immunology. 175(5). 3075–3083. 163 indexed citations

17.

Kawamura, Hiroki, Fred Aswad, Masahiro Minagawa, et al.. (2005). P2X7 Receptor-Dependent and -Independent T Cell Death Is Induced by Nicotinamide Adenine Dinucleotide. The Journal of Immunology. 174(4). 1971–1979. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact